Adiponectin inhibits migration and invasion by reversing epithelial‑mesenchymal transition in non‑small cell lung carcinoma

Cui,Enhai; Guo,Huihui; Shen,Mo; Yu,Huanming; Gu,Donghua; Mao,Wei; Wang,Xiang

doi:10.3892/or.2018.6523

Adiponectin inhibits migration and invasion by reversing epithelial‑mesenchymal transition in non‑small cell lung carcinoma

Authors:
- Enhai Cui
- Huihui Guo
- Mo Shen
- Huanming Yu
- Donghua Gu
- Wei Mao
- Xiang Wang
View Affiliations

Affiliations: Department of Respiratory Medicine, Huzhou Central Hospital, Huzhou, Zhejiang 313000, P.R. China, Center of Clinical Laboratory, The First People's Hospital of Huzhou, Huzhou Teachers College, Huzhou, Zhejiang 313000, P.R. China, Department of Medical Laboratory, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang 325000, P.R. China, Center of Clinical Laboratory, The First People's Hospital of Huzhou, Huzhou Teachers College, Huzhou, Zhejiang 313000, P.R. China, Department of Respiratory Medicine, Huzhou Central Hospital, Huzhou, Zhejiang 313000, P.R. China
Published online on: June 25, 2018 https://doi.org/10.3892/or.2018.6523
Pages: 1330-1338
Copyright: © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adiponectin is the most abundant adipokine in the tumor microenvironment. The role of this protein in tumor progression, however, remains controversial. In the present study, we aimed to investigate the effects of adiponectin on the abilities of migration and invasion in non‑small cell lung carcinoma (NSCLC). Using NSCLC cell lines, we examined the effects of adiponectin on cell migration and invasion using Transwell assays. Expression of epithelial‑mesenchymal transition markers was examined via microscopy and western blotting. We also performed a knockdown of Twist, AdipoR1 and AdipoR2 in NSCLC cells with siRNAs. The addition of adiponectin to NSCLC cells inhibited both the migration and invasion abilities. Furthermore, we found that NSCLC cells displayed increased epithelial marker expression and downregulation of mesenchymal marker expression following adiponectin administration. Twist AdipoR1 and AdipoR2 knockdown reversed the inhibitory effects of adiponectin on migration and invasion in NSCLC and epithelial‑mesenchymal transition. Exogenous adiponectin significantly impaired the migratory and invasive capacities of NSCLC cells through reversal of EMT, suggesting that adiponectin may be a novel promising therapeutic approach against NSCLC.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Abdel-Raheem MM, Potti A, Becker WK, Saberi A, Scilley BS and Mehdi SA: Late adrenal metastasis in operable non-small-cell lung carcinoma. Am J Clin Oncol. 25:81–83. 2002. View Article : Google Scholar : PubMed/NCBI
4	National Lung Screening Trial Research Team, ; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
5	Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med. 350:379–392. 2004. View Article : Google Scholar : PubMed/NCBI
6	Li MJ, He Q, Li M, Luo F and Guan YS: Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. Onco Targets Ther. 9:1291–1302. 2016.PubMed/NCBI
7	Abdullah MM, Bhat A, Mohamed AK, Ching FY, Ahmed N and Gantotti S: Gefitinib as first line therapy in Malaysian patients with mutation-positive non-small-cell lung cancer: A single-center retrospective study. Oncol Lett. 11:2757–2762. 2016. View Article : Google Scholar : PubMed/NCBI
8	Yu T, Guo Z, Fan H, Song J, Liu Y, Gao Z and Wang Q: Cancer-associated fibroblasts promote non-small cell lung cancer cell invasion by upregulation of glucose-regulated protein 78 (GRP78) expression in an integrated bionic microfluidic device. Oncotarget. 7:25593–25603. 2016.PubMed/NCBI
9	Bertolini G, D'Amico L, Moro M, Landoni E, Perego P, Miceli R, Gatti L, Andriani F, Wong D, Caserini R, et al: : Microenvironment-modulated metastatic CD133⁺/CXCR4⁺/EpCAM-lung cancer-initiating cells sustain tumor dissemination and correlate with poor prognosis. Cancer Res. 75:3636–3649. 2015. View Article : Google Scholar : PubMed/NCBI
10	Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y, Tatsumi K, Koide S, Iwama A and Takiguchi Y: Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. Int J Oncol. 48:1825–1836. 2016. View Article : Google Scholar : PubMed/NCBI
11	Folco EJ, Rocha VZ, López-Ilasaca M and Libby P: Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of interleukin-10. J Biol Chem. 284:25569–25575. 2009. View Article : Google Scholar : PubMed/NCBI
12	Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y and Matsuzawa Y: Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 96:1723–1732. 2000.PubMed/NCBI
13	Kelesidis I, Kelesidis T and Mantzoros CS: Adiponectin and cancer: A systematic review. Br J Cancer. 94:1221–1225. 2006. View Article : Google Scholar : PubMed/NCBI
14	Barb D, Williams CJ, Neuwirth AK and Mantzoros CS: Adiponectin in relation to malignancies: A review of existing basic research and clinical evidence. Am J Clin Nutrit. 86 Suppl:S858–S866. 2007. View Article : Google Scholar : PubMed/NCBI
15	Tang CH and Lu ME: Adiponectin increases motility of human prostate cancer cells via adipoR, p38, AMPK, and NF-kappaB pathways. Prostate. 69:1781–1789. 2009. View Article : Google Scholar : PubMed/NCBI
16	Umekawa K, Kimura T, Kudoh S, Suzumura T, Nagata M, Mitsuoka S, Matsuura K, Oka T, Yoshimura N, Kira Y and Hirata K: Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs. Osaka City Med J. 59:53–60. 2013.PubMed/NCBI
17	Vansaun MN: Molecular pathways: Adiponectin and leptin signaling in cancer. Clin Cancer Res. 19:1926–1932. 2013. View Article : Google Scholar : PubMed/NCBI
18	Otani K, Kitayama J, Yasuda K, Nio Y, Iwabu M, Okudaira S, Aoki J, Yamauchi T, Kadowaki T and Nagawa H: Adiponectin suppresses tumorigenesis in Apc^Min/+ mice. Cancer Lett. 288:177–182. 2010. View Article : Google Scholar : PubMed/NCBI
19	Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, Gershenson DM and Lu KH: Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 106:2376–2381. 2006. View Article : Google Scholar : PubMed/NCBI
20	Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K and Nagawa H: Plasma adiponectin and gastric cancer. Clin Cancer Res. 11:466–472. 2005.PubMed/NCBI
21	Kim KY, Baek A, Hwang JE, Choi YA, Jeong J, Lee MS, Cho DH, Lim JS, Kim KI and Yang Y: Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res. 69:4018–4026. 2009. View Article : Google Scholar : PubMed/NCBI
22	Barb D, Neuwirth A, Mantzoros CS and Balk SP: Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer. 14:995–1005. 2007. View Article : Google Scholar : PubMed/NCBI
23	Landskroner-Eiger S, Qian B, Muise ES, Nawrocki AR, Berger JP, Fine EJ, Koba W, Deng Y, Pollard JW and Scherer PE: Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res. 15:3265–3276. 2009. View Article : Google Scholar : PubMed/NCBI
24	Denzel MS, Hebbard LW, Shostak G, Shapiro L, Cardiff RD and Ranscht B: Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clin Cancer Res. 15:3256–3264. 2009. View Article : Google Scholar : PubMed/NCBI
25	Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, et al: Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 17:55–63. 2011. View Article : Google Scholar : PubMed/NCBI
26	Ribeiro R, Araújo AP, Coelho A, Catarino R, Pinto D, Araújo A, Calçada C, Lopes C and Medeiros R: A functional polymorphism in the promoter region of leptin gene increases susceptibility for non-small cell lung cancer. Eur J Cancer. 42:1188–1193. 2006. View Article : Google Scholar : PubMed/NCBI
27	Shih CM, Lee YL, Chiou HL, Chen W, Chang GC, Chou MC and Lin LY: Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer. 52:15–20. 2006. View Article : Google Scholar : PubMed/NCBI
28	Cui E, Deng A, Wang X, Wang B, Mao W, Feng X and Hua F: The role of adiponectin (ADIPOQ) gene polymorphisms in the susceptibility and prognosis of non-small cell lung cancer. Biochem Cell Biol. 89:308–313. 2011. View Article : Google Scholar : PubMed/NCBI
29	Gioulbasanis I, Georgoulias P, Vlachostergios PJ, Baracos V, Ghosh S, Giannousi Z, Papandreou CN, Mavroudis D and Georgoulias V: Mini nutritional assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: Interrelations and associations with prognosis. Lung Cancer. 74:516–520. 2011. View Article : Google Scholar : PubMed/NCBI
30	Bruera E: ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ. 315:1219–1222. 1997. View Article : Google Scholar : PubMed/NCBI
31	Batista ML Jr, Olivan M, Alcantara PS, Sandoval R, Peres SB, Neves RX, Silverio R, Maximiano LF, Otoch JP and Seelaender M: Adipose tissue-derived factors as potential biomarkers in cachectic cancer patients. Cytokine. 61:532–539. 2013. View Article : Google Scholar : PubMed/NCBI
32	Sun Y and Lodish HF: Adiponectin deficiency promotes tumor growth in mice by reducing macrophage infiltration. PloS One. 5:e119872010. View Article : Google Scholar : PubMed/NCBI
33	Peng J, Tsang JY, Ho DH, Zhang R, Xiao H, Li D, Zhu J, Wang F, Bian Z, Lui VC, et al: Modulatory effects of adiponectin on the polarization of tumor-associated macrophages. Int J Cancer. 137:848–858. 2015. View Article : Google Scholar : PubMed/NCBI
34	Tan PH, Tyrrell HE, Gao L, Xu D, Quan J, Gill D, Rai L, Ding Y, Plant G, Chen Y, et al: Adiponectin receptor signaling on dendritic cells blunts antitumor immunity. Cancer Res. 74:5711–5722. 2014. View Article : Google Scholar : PubMed/NCBI
35	Shibata S, Tada Y, Hau CS, Mitsui A, Kamata M, Asano Y, Sugaya M, Kadono T, Masamoto Y, Kurokawa M, et al: Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from gammadelta-T cells. Nat Commun. 6:76872015. View Article : Google Scholar : PubMed/NCBI